According to J.P. Morgan, BioMimetic Therapeutics BMTI has its work cut out for it.
J.P. Morgan said that after a long day of debate, BioMimetic's Augment bone graft received a marginally favorable FDA panel vote Thursday evening. “The panel (n=18) voted on each of: (1) safety; (2) efficacy; and finally (3) the overall risk benefit profile of Augment. The safety vote was 12-6 in favor, while the efficacy and overall vote were a closer 10-8 in support of BMTI's data package.”
BioMimetic Therapeutics closed yesterday at $4.68.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in